Sarcoma

P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2026 --> Dec 2026

P2, N=20, Recruiting, Memorial Sloan Kettering Cancer Center

P1/2, N=94, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting

P2, N=36, Recruiting, Mayo Clinic | Suspended --> Recruiting

P2, N=15, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2027 --> Jun 2027 | Initiation date: Dec 2025 --> Sep 2025

P=N/A, N=143, Not yet recruiting, Dana-Farber Cancer Institute

DOG1-positive CAFs were associated with better overall survival. This study suggests that DOG1 expression is detected in a high proportion of CRC because it is expressed in neoplastic cells of various histological subtypes of CRC that secrete gel-forming mucins, independently of mucinous features or in CAFs of conventional adenocarcinomas.

No recurrence was noted at 6-month follow-up. This case underscores the diagnostic challenge of GSS, the critical role of molecular techniques and the efficacy of minimally invasive surgical management.

The eIF4A inhibitor CR-1-31B effectively suppressed tumor growth and induced apoptosis in DDLS, MFS, and UPS patient-derived cell lines and mouse xenografts...Genomic analysis of patient tumors revealed that YAP and WWTR1 were frequently amplified or gained in DDLS, MFS, and UPS and were associated with worse clinical outcomes. Together, our findings identify a new strategy for targeting the Hippo pathway in incurable forms of sarcoma based on inhibition of eIF4A-dependent translation of the key oncogenic transcription factors YAP and TAZ.

This study demonstrates that ITCH functions as an oncogene in OS by targeting P53 for degradation, and suggests ITCH as a promising therapeutic target. Implications: These findings define a molecular mechanism underlying the oncogenic role of ITCH through P53 ubiquitination-dependent degradation.

We report the first case of a patient with OD in whom PHPT was diagnosed and associated with the presence of an IDH1 mutation detected in a parathyroid adenoma. This observation suggests a possible role of IDH1 mutations in parathyroid tumorigenesis in OD and underscores the need to consider endocrine manifestations in this condition.

rPNET in adults is a rare, aggressive entity that is frequently diagnosed at an advanced stage. A multimodal strategy of surgery when feasible plus systemic multi-agent CT, with radiotherapy in selected cases, should be planned upfront in specialised centres by a multidisciplinary team.